The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate Cancer

Global Inclusion Criteria: * Resident of Canada * Male sex * Age 18 years or older * Previously diagnosed with prostate cancer, under referring physician's care * ECOG performance status 0 - 3, inclusive * Able to understand and provide written informed consent * Able to tolerate the physical/logistical requirements of completing a PET/CT scan including lying supine (or prone) for up to 40 minutes and tolerating intravenous cannulation for injection Global Exclusion Criteria: * Patients who are medically unstable (e.g. acute cardiac or respiratory distress or hypotensive) * Patients who exceed the safe weight limit of the PET/CT bed (usually approximately 400 lbs.) or who cannot fit through the PET/CT bore (usually approximately 70 cm diameter) * Patients who are claustrophobic. Clinical Indication Criteria Subgroups: * BCR: Biochemical recurrence as defined by serum PSA \> 1 ng/ml following either radical prostatectomy or curative-intent radiotherapy or other prostate-ablative definitive management. * HRS: Staging of high risk patients as defined by any one of the following: * Gleason score \> 7 * Serum PSA \> 15 ng/ml * T stage of T3 or greater on TNM staging * Equivocal conventional staging such as CT, MRI or bone scan * Clinical suspicion of advance stage disease (e.g. bone pain)